Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Rose McGready, Deputy Director of the Shoklo Malaria Research Unit (SMRU), part of the MORU Tropical Health Network within Oxford’s Nuffield Department of Medicine, has been honoured with the 2026 Australian Capital Territory (ACT) Australian of the Year Award.

Professor Rose McGready receiving the award

The award recognises her extraordinary three decades of service to displaced and marginalised communities along the Thai-Myanmar border, and her clinical and research, that has saved the lives of countless mothers and babies while shaping global standards of care.

Reflecting on her journey, Professor McGready said “I came for 6 months to the Thai–Myanmar border and it’s been more than 30 years, thanks to the incredibly brave Karen and Burmese women.”

Professor McGready works alongside Karen and Burmese communities who have fled violence, human rights abuses and poverty in Myanmar. Despite crossing into Thailand, many migrants continue to face significant barriers in accessing public health services, with pregnant women, newborns, and young children among the most vulnerable.

Through her work she has established a network of community-run clinics delivering essential maternal and child healthcare, infectious disease prevention, and life-saving treatment. These services have supported thousands of women and children, dramatically improving health outcomes across the region.

 

Read the full story on the Nuffield Department of Medicine website.

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.